Codiak BioSciences, an early stage biotech developing exosome therapeutics for various diseases, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol CDAK. Codiak BioSciences filed confidentially on March 6, 2019. Jefferies, Evercore ISI and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.
